Search

Displaying results 1451 - 1460 of 4262 in total
  1. Drug

    Betula pendula tar oil

    go.drugbank.com/drugs/DB11361
    ApprovedNutraceutical

    This oil is usually obtained by using both hydrodistillation and micro-distillation[A33154] and it is conformed mainly by [DB11143] and [DB11359]. … [L1113] By the FDA, it is considered under the substances approved to be added to the food.

  2. Drug

    Dienogest

    go.drugbank.com/drugs/DB09123
    ApprovedInvestigational

    It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself.

  3. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

  4. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

  5. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  6. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. … The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization.

  7. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.

  8. Drug

    Methyldopa

    go.drugbank.com/drugs/DB00968
    ApprovedInvestigational

    Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].

  9. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    [A6921] Ofatumumab was first approved by the FDA in 2009. … [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells.

  10. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa).